NCT07366099 Al18F-NOTA-LM3 PET/CT in Patients With TIO
| NCT ID | NCT07366099 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking Union Medical College Hospital |
| Condition | Tumor-Induced Osteomalacia |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2023-03-30 |
| Primary Completion | 2026-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2023-03-30 with a primary completion date of 2026-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a pilot study to assess the value of whole-body Al18F-NOTA-LM3 PET/CT in patients with tumor-induced osteomalacia.
Eligibility Criteria
Inclusion Criteria: * Patients aged 18 to 80 years. * Suspected or confirmed TIO patients. Exclusion Criteria: * Combined with other types of tumors. * Severe liver or renal dysfunction (ALT/AST≥5 ULN, GFR\<30ml/min). * Pregnant or breast-feeding women. * Inability to perform PET/CT scans.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07366099 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Tumor-Induced Osteomalacia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07366099 currently recruiting?
Yes, NCT07366099 is actively recruiting participants. Contact the research team at annsmile1976@sina.com for enrollment information.
Where is the NCT07366099 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07366099 clinical trial?
NCT07366099 is sponsored by Peking Union Medical College Hospital. The trial plans to enroll 40 participants.